What is Ligand Pharmaceuticals Incorporated's (LGND) StockRank?

MoatMap's StockRank for Ligand Pharmaceuticals Incorporated (LGND) is 67/100, with a Buy signal. This is a composite score combining Quality (64), Value (26), and Momentum (72) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Ligand Pharmaceuticals Incorporated have an economic moat?

Ligand Pharmaceuticals Incorporated (LGND) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Ligand Pharmaceuticals Incorporated a buy, hold, or sell?

MoatMap's current signal for Ligand Pharmaceuticals Incorporated (LGND) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Ligand Pharmaceuticals Incorporated in?

Ligand Pharmaceuticals Incorporated (LGND) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

LGND

BuyPremium Grower

Ligand Pharmaceuticals Incorporated · Healthcare · United States · $5.6B · Avg Vol: $66M/d

StockRank

Get insider-trade alerts

P/E (TTM)

29.4x

ROE

22.0%

D/E

1.2x

Dividend %

—

COMPANY DESCRIPTION

Ligand Pharmaceuticals Incorporated operates a unique royalty-based business model, focusing on developing and licensing proprietary drug discovery and development platforms to pharmaceutical partners. Its primary competitive moat is built around its patented Captisol® technology, which significantly enhances drug solubility and stability, making it a crucial component in numerous approved and pipeline drug products. This intellectual property-centric approach generates revenue through royalties on partners' sales rather than costly direct drug development.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	196.2M	131.3M	167.1M	268.1M	11.0%	290.5M	289.8M	380.5M	19.1%
EPS	-1.98	3.02	-0.22	6.44	46.0%	9.71	7.38	9.45	21.2%
Shares	17.0M	17.6M	19.1M	19.8M	+16.7%	19.9M	—	—	—
Debt	87.7M	6.2M	7.1M	451.5M	72.6%	1.1B	—	—	—
Equity	597.5M	700.9M	830.4M	1.0B	19.4%	—	—	—	—
Op CF	137.8M	49.6M	97.0M	49.4M	-29.0%	131.7M	—	—	—
Inv CF	163.6M	-11.7M	-143.7M	-377.3M	—	—	—	—	—
Fin CF	-276.0M	-59.9M	97.1M	428.2M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+0.0%

SMA 50SMA 200

$288.05

RSI (14)

46.9

52W High

$326.63

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

16.0%85.2

ROE

22.0%90.1

GP/Assets

15.1%34.8

Op. Margin

13.5%71.4

FCF/Assets

7.7%80.1

Piotroski

549.3

Int. Cover

39.4x76.5

D/E Ratio

1.17x11.5

Current Ratio

31.18x98.1

Value

P/E (TTM)

29.4x40.9

EV/EBITDA

41.1x14.8

P/FCF

46.7x30.8

P/B

5.9x23.5

P/S

19.6x16.4

Div Yield

—N/A

Momentum

52W High %

88%82.2

RS 6M

23%82.2

SMA 50/200

1.27x91.9

EPS Rev 4W

-1.0%25.2

EPS Rev 12W

+5.5%80.5

EPS Improve

+23%36.4

Q Growth

901%98.1

FUNDAMENTALS

Market Cap

$5.6B

P/E (Forward)

23.9x

Gross Margin

81.2%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LGND are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
LGND	Ligand Pharmaceuticals Incorporated(you)	$5.6B	67	Buy
CAI	Caris Life Sciences, Inc.	$7.2B	60	Hold
TVTX	Travere Therapeutics, Inc.	$6.2B	54	Hold
ACAD	ACADIA Pharmaceuticals Inc.	$5.0B	83	Strong Buy
TGTX	TG Therapeutics, Inc.	$8.3B	57	Hold
KRYS	Krystal Biotech, Inc.	$10.4B	74	Buy
CORT	Corcept Therapeutics Incorporated	$12.3B	71	Buy
BMRN	BioMarin Pharmaceutical Inc.	$12.5B	63	Hold
TECH	Bio-Techne Corporation	$11.3B	76	Buy
BLTE	Belite Bio, Inc	$6.1B	42	Hold

Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%

Ligand Pharmaceuticals Incorporated (LGND): Stock Score Summary

Ligand Pharmaceuticals Incorporated (LGND) has a MoatMap StockRank of 67/100 based on Quality (64/100), Value (26/100), and Momentum (72/100) factor scores. The current signal is BUY.

Key Financial Metrics

Price	$288.05
Market Cap	$5.6B
P/E (TTM)	29.41
P/E (Forward)	23.93
Price/Book	5.88
Return on Equity	22.0%
Return on Invested Capital	16.0%
Debt/Equity	1.17x
Gross Margin	81.2%
Operating Margin	13.5%
Revenue Growth	33.7%
Free Cash Flow	$120M

Ligand Pharmaceuticals Incorporated operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Ligand Pharmaceuticals Incorporated’s (LGND) StockRank?: MoatMap’s StockRank for Ligand Pharmaceuticals Incorporated (LGND) is 67/100, with a Buy signal. It is a composite of Quality (64), Value (26), and Momentum (72) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Ligand Pharmaceuticals Incorporated have an economic moat?: Ligand Pharmaceuticals Incorporated (LGND) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Ligand Pharmaceuticals Incorporated a buy, hold, or sell?: MoatMap’s current signal for Ligand Pharmaceuticals Incorporated (LGND) is Buy, based on a StockRank of 67/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Ligand Pharmaceuticals Incorporated in?: Ligand Pharmaceuticals Incorporated (LGND) operates in the Healthcare sector, specifically the Biotechnology industry (United States).